Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis

M. Stork, I. Spicka, J. Radocha, J. Minarik, T. Jelinek, A. Jungova, P. Pavlicek, L. Pospisilova, F. Sedlak, J. Straub, T. Pika, Z. Knechtova, A. Fidrichova, I. Boichuk, S. Sevcikova, V. Maisnar, R. Hajek, L. Pour

. 2023 ; 102 (6) : 1501-1511. [pub] 20230424

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011197

Grantová podpora
NU21-03-00076 Ministerstvo Zdravotnictví Ceské Republiky
FNBr Ministerstvo Zdravotnictví Ceské Republiky
65269705 Ministerstvo Zdravotnictví Ceské Republiky
LX22NPO5102 European Union

We performed real world evidence (RWE) analysis of daratumumab, lenalidomide and dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in relapsed/refractory multiple myeloma patients (RRMM). In total, 240 RRMM patients were treated with Dara-Rd from 2016 to 2022 outside of clinical trials in all major Czech hematology centers. As a reference, 531 RRMM patients treated with Rd were evaluated. Patients' data were recorded in the Czech Registry of Monoclonal Gammopathies (RMG). Partial response (PR) or better response (ORR) was achieved in significantly more patients in Dara-Rd than in Rd group (91.2% vs. 69.9%; p < 0.001). The median progression free survival (PFS) was 26.9 months in the Dara-Rd and 12.8 months in the Rd group (p < 0.001). Median overall survival (OS) was not reached in the Dara-Rd compared to 27.2 months in the Rd group (p = 0.023). In patients with 1-3 previous treatment lines, there was significant PFS benefit of Dara-Rd compared to Rd (median PFS not reached vs. 13.2 months; p < 0.001). In patients with > 3 previous treatment lines, there was no significant PFS benefit of Dara-Rd treatment (7.8 months vs. 9.9 months; p = 0.874), similarly in patients refractory to PI + IMIDs (11.5 months vs. 9.2 months; p = 0.376). In RWE conditions, the median PFS in RRMM patients treated with Dara-Rd is shorter when compared to clinical trials. In heavily pretreated RRMM patients, efficacy of Dara-Rd treatment is limited; best possible outcomes of Dara-Rd are achieved in minimally pretreated patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011197
003      
CZ-PrNML
005      
20230801132851.0
007      
ta
008      
230718s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-023-05188-4 $2 doi
035    __
$a (PubMed)37088816
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic
245    10
$a Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis / $c M. Stork, I. Spicka, J. Radocha, J. Minarik, T. Jelinek, A. Jungova, P. Pavlicek, L. Pospisilova, F. Sedlak, J. Straub, T. Pika, Z. Knechtova, A. Fidrichova, I. Boichuk, S. Sevcikova, V. Maisnar, R. Hajek, L. Pour
520    9_
$a We performed real world evidence (RWE) analysis of daratumumab, lenalidomide and dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in relapsed/refractory multiple myeloma patients (RRMM). In total, 240 RRMM patients were treated with Dara-Rd from 2016 to 2022 outside of clinical trials in all major Czech hematology centers. As a reference, 531 RRMM patients treated with Rd were evaluated. Patients' data were recorded in the Czech Registry of Monoclonal Gammopathies (RMG). Partial response (PR) or better response (ORR) was achieved in significantly more patients in Dara-Rd than in Rd group (91.2% vs. 69.9%; p < 0.001). The median progression free survival (PFS) was 26.9 months in the Dara-Rd and 12.8 months in the Rd group (p < 0.001). Median overall survival (OS) was not reached in the Dara-Rd compared to 27.2 months in the Rd group (p = 0.023). In patients with 1-3 previous treatment lines, there was significant PFS benefit of Dara-Rd compared to Rd (median PFS not reached vs. 13.2 months; p < 0.001). In patients with > 3 previous treatment lines, there was no significant PFS benefit of Dara-Rd treatment (7.8 months vs. 9.9 months; p = 0.874), similarly in patients refractory to PI + IMIDs (11.5 months vs. 9.2 months; p = 0.376). In RWE conditions, the median PFS in RRMM patients treated with Dara-Rd is shorter when compared to clinical trials. In heavily pretreated RRMM patients, efficacy of Dara-Rd treatment is limited; best possible outcomes of Dara-Rd are achieved in minimally pretreated patients.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x diagnóza $x farmakoterapie $7 D009101
650    _2
$a lenalidomid $x terapeutické užití $7 D000077269
650    _2
$a dexamethason $x škodlivé účinky $7 D003907
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
655    _2
$a časopisecké články $7 D016428
700    1_
$a Spicka, Ivan $u 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic
700    1_
$a Radocha, Jakub $u 4th Department of Medicine - Hematology, Faculty of Medicine, Charles University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Jelinek, Tomas $u Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Jungova, Alexandra $u Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic
700    1_
$a Pavlicek, Petr $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Pospisilova, Lenka $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Sedlak, Frantisek $u 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic
700    1_
$a Straub, Jan $u 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic
700    1_
$a Pika, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Knechtova, Zdenka $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Fidrichova, Anna $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Boichuk, Ivanna $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Sevcikova, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000271946771
700    1_
$a Maisnar, Vladimir $u 4th Department of Medicine - Hematology, Faculty of Medicine, Charles University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Hajek, Roman $u Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic. Pour.ludek@fnbrno.cz $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Pour.ludek@fnbrno.cz
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 102, č. 6 (2023), s. 1501-1511
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37088816 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132848 $b ABA008
999    __
$a ok $b bmc $g 1963532 $s 1197462
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 102 $c 6 $d 1501-1511 $e 20230424 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
GRA    __
$a NU21-03-00076 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a FNBr $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a LX22NPO5102 $p European Union
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace